Biotechnology
Company Overview of Protagonist Therapeutics, Inc.
Company Overview
Protagonist Therapeutics, Inc., a biotechnology company, engages in the discovery and development of disulfide rich peptides (DRP), various alternatives to antibodies, and new chemical entities against those targets and life threatening diseases. It applies its DRP technology platform to the discovery and preclinical development of injectable and orally stable IL-6 peptide antagonists; and to identify orally stable DRPs against gastrointestinal targets linked to disease, as well as for identifying specific targets from the ion channel, GPCR, and cytokine families. The company was founded in 2001 and is based in Palo Alto, California.
3941 East Bayshore Road
Palo Alto, CA 94303
United States
Founded in 2001
Key Executives for Protagonist Therapeutics, Inc.
Protagonist Therapeutics, Inc. Key Developments
Protagonist Therapeutics, Inc. Presents at EBD Group AG's Biotech showcase 2013, Jan-07-2013 02:00 PM. Venue: Parc 55 Wyndham Union Square Hotel, San Francisco, California, United States.
Protagonist Therapeutics, Inc. and Ironwood Pharmaceuticals, Inc. announced the expansion of their research collaboration. The collaboration, originally announced in January 2011, leverages Protagonist's proprietary disulfide-rich peptide (DRP) technology platform and is aimed at providing Ironwood with novel peptides against targets for potential development in therapeutic areas with significant unmet medical needs. As previously announced, Protagonist and Ironwood are using Protagonist's DRP technology platform to design, discover and optimize novel peptides against therapeutically relevant targets. Researchers from both companies are working together as part of an integrated team that includes Protagonist scientists funded by Ironwood for the duration of the collaboration period. Ironwood has the right to advance such peptide therapeutic candidates through preclinical and clinical development, and if successfully developed and approved by regulatory authorities, commercialization. Pending the achievement of certain development and commercialization milestones, Ironwood will make certain milestone payments and pay royalties on sales of each product identified using Protagonist's technology.
Protagonist Therapeutics, Inc. Presents at The 11th Annual BIO Investor Forum 2012, Oct-10-2012 11:30 AM. Venue: Palace Hotel, 2 New Montgomery Street, San Francisco, CA 94105, United States.
Similar Private Companies By Industry
| Company Name | Region |
| Aduro BioTech, Inc. | United States |
| Latam Clinical Trials, Inc. | United States |
| Paloma Pharmaceuticals, Inc. | United States |
| TAXIS Pharmaceuticals, Inc. | United States |
| Prologue Research International, Inc. | United States |
Recent Private Companies Transactions
| Type Date |
Target | |
| No transactions available in the past 12 months. | ||
Most Searched Private Companies
| Company Name | Geographic Region |
| NYC2012, Inc. | United States |
| Bertelsmann AG | Europe |
| Lawyers Committee for Civil Rights Under Law | United States |
| Rush University | United States |
| Citizens Budget Commission | United States |
Post a JobJobs
- Adelphi, MD | University of Maryland University CollegePosted: May 07
- Seattle, WA | Marina Sirras & AssociatesPosted: Apr 09
- Tarrytown, NY | BASFPosted: May 22
- San Francisco, CA | Confidential Biotechnology CompanyPosted: May 13
Sponsored Financial Commentaries
Sponsored Links
To contact Protagonist Therapeutics, Inc., please visit www.protagonist-inc.com. Company data is provided by Capital IQ. Please use this form to report any data issues.
Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.
